A robust, translatable model of inflammatory arthritis is essential for the definitive evaluation of novel immunomodulatory and anti-inflammatory agents. At BioLegacy, we center these studies on the gold-standard collagen-induced arthritis (CIA) model in both mice and rats, which closely recapitulates the key pathological and immunological hallmarks of human rheumatoid arthritis. Integrating comprehensive clinical scoring with quantitative histopathology and in-depth biomarker analysis, we provide a clear and robust data package on your therapeutic’s efficacy.
BioLegacy provides a precise understanding of a compound’s anti-inflammatory mechanism. Our definitive characterizations are underpinned by a comprehensive suite of extensively validated acute and chronic inflammation models. Our expertise in dissecting innate and adaptive immune responses — from TLR4-mediated systemic inflammation to NLRP3 inflammasome activation — delivers the clear, quantitative data on cytokine modulation, cellular infiltration, and therapeutic efficacy that is essential for de-risking your program and confirming its mechanism of action.
A quantitative assessment of a compound’s ability to modulate T-cell mediated inflammation is a critical step for many immunology programs. BioLegacy provides this definitive data using gold-standard models of delayed-type hypersensitivity (DTH), a well-established readout of antigen-specific T-cell recall responses. Our expertise in these highly reproducible contact hypersensitivity models delivers a clear, in vivo measure of your therapeutic’s immunomodulatory efficacy, providing the data needed to advance your program with confidence.
A therapeutic’s ability to modulate intense, systemic inflammatory cascades is a critical measure of its potential in critical care indications. At BioLegacy, we provide a definitive assessment of these potent immunomodulatory effects using gold-standard, clinically relevant models of systemic inflammation. Our expertise in endotoxemia and polymicrobial sepsis models provides robust evaluation of your compound’s capacity to suppress cytokine storms, prevent multi-organ failure, and improve survival, delivering the pivotal data required for your program’s advancement.
A definitive in vivo assessment of a therapeutic’s ability to modulate CNS autoimmunity is central to any neuroimmunology program. BioLegacy provides this critical data using the gold-standard Experimental Autoimmune Encephalomyelitis (EAE) model, the most widely accepted platform for multiple sclerosis research. Our expertise across various EAE models allows for a robust evaluation of your compound’s capacity to prevent disease onset, mitigate relapse, and inhibit the core pathological drivers of demyelination and axonal damage, delivering pivotal, translatable efficacy data.
BioLegacy supports dermatology programs with quantitative evaluations of a therapeutic’s impact on the complex immunopathology of dermal inflammation. Our definitive assessments leverage a suite of highly translatable in vivo skin inflammation models, from classic hapten-induced dermatitis to sophisticated TLR7-mediated psoriasis and human psoriatic skin graft models. This provides a robust characterization of your compound’s ability to modulate key inflammatory pathways and resolve pathological phenotypes.
Reliable preclinical assessments of therapeutics for chronic airway disease require models that accurately recapitulate the underlying pathophysiology of inflammation, hyperresponsiveness, and lung remodeling. BioLegacy provides these critical evaluations with a suite of extensively validated asthma and COPD models. Our deep expertise in these platforms, from classic allergen-induced asthma to smoke-induced COPD, delivers quantitative, mechanistic data on immune cell infiltration, mucus hypersecretion, and airway function. Advance your respiratory program with confidence!
